JackJawdatKhouriMDFACP

Hematologic Oncology

Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Dr. Khouri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Jack Khouri is an oncologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from University of Balamand Faculty of Medicine and has been in practice 5 years. He specializes in hematologic oncology, bone marrow transplantation and apheresis medicine.

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2016 - 2019
Tufts Medical CenterResidency, Internal Medicine, 2013 - 2016
University of Balamand Faculty of MedicineClass of 2012

Fellow of the American College of Physicians ACP, 2024
Teacher of the Year Award Cleveland Clinic Hematology/Medical Oncology Fellowship, 2020
Excellence in Teaching Cleveland Clinic Internal Medicine Residency Program, 2018
Best Poster Presentation Society of General Internal Medicine (SGIM), 2015
Excellence in Teaching Tufts University School of Medicine, 2014
Join now to see all

PubMed

Journal Articles

AL Amyloidosis: Diagnosis and Therapeutic Advances
Jack Khouri, Clinical Hematology Update, New England Journal of Medicine Group, 12/2023
Neutropenic Fever During Peripheral Blood Progenitor Cell Mobilization Is Associated with Decreased CD34+ Cell Collection and Increased Apheresis Collection Days
Mat Kalaycio, Robert Dean, Jack Khouri, Brad Pohlman, Aleksandr Lazaryan, Edward Copelan, Steven Andresen, Ronald Sobecks, Hien Liu, Journal of Clinical Apheresis
Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days
Khouri J, Rybicki L, Majhail N, Kalaycio M, Copelan E, Pohlman B, Hill B, Dean R, Lazaryan A, Hamilton B, Andresen S, Sobecks R, Bolwell B, Liu H, Journal of Clinical Apheresis, 11/2017

Abstracts/Posters

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
Jack Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis
Jack Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients
Jack Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real World Data on the Safety and Efficacy of Pomalidomide as a Single Agent and in Combination with Corticosteroids in Relapsed and Refractory Multiple Myeloma
Tahani Atieh, Anne Hubbe, Wei Wei, Beth Faiman, Christy Joy Samaras, Jason Valent, Jack Khouri, Clinical Lymphoma, Myeloma and Leukemia, Boston, MA, 9/2019
Join now to see all

Lectures

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma
12/1/2018

Perspective: Teclistamab confers durable benefit in advanced multiple myeloma. Haelio. June 17, 2022June 2022
Unprecedented Advances Fuel Progress in the Treatment of AL AmyloidosisFebruary 2022

Upping the Ante with Bispecific and Trispecific AntibodiesAugust 6th, 2024
Khouri Highlights the Ongoing AFFIRM-AL Trial in AL AmyloidosisNovember 9th, 2023
‘Thought I Was Dying’: Woman Goes from Wheelchair to Walking Again After Symptoms Puzzle Dozens of DoctorsMarch 11th, 2021
Join now to see all

Phase II trial of siltuximab for cytokine release syndrome prophylaxis prior to treatment with teclistamab in relapsed or refractory multiple myeloma (RRMM)Recordati2024–Present